REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights

Rhea-AI Summary

REGENXBIO (Nasdaq: RGNX) has scheduled a conference call for Thursday, August 7, 2025, at 8:00 a.m. ET to discuss its second quarter 2025 financial results and recent operational developments. The company will host a webcast that can be accessed through a registration link.

Analysts can participate in the Q&A session by dialing (646) 307-1963 (domestic) or (800) 715-9871 (international) with passcode 9571992. A replay will be available on REGENXBIO's investor website approximately two hours after the call concludes. Participants are encouraged to join 15 minutes before the start time.

News Market Reaction

-2.74%

1 alert

-2.74% News Effect

On the day this news was published, RGNX declined 2.74%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

ROCKVILLE, Md., July 31, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, August 7, at 8:00 a.m. ET to discuss its financial results for the second quarter ended June 30, 2025, and operational highlights.

Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should access the live call by dialing (646) 307-1963 (domestic) or (800) 715-9871 (international) and enter the passcode 9571992. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.

ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.

Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com 

Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-august-7-to-discuss-second-quarter-2025-financial-results-and-operational-highlights-302518467.html

SOURCE REGENXBIO Inc.

FAQ

When is REGENXBIO (RGNX) reporting Q2 2025 earnings?

REGENXBIO will report Q2 2025 earnings on Thursday, August 7, 2025, at 8:00 a.m. ET via a conference call and webcast.

How can investors access REGENXBIO's Q2 2025 earnings call?

Investors can access the webcast through a registration link. Analysts can dial (646) 307-1963 (domestic) or (800) 715-9871 (international) with passcode 9571992.

Will there be a replay of REGENXBIO's Q2 2025 earnings call?

Yes, a replay of the webcast will be available on REGENXBIO's investor website approximately two hours after the call's conclusion.

What time should participants join REGENXBIO's Q2 2025 earnings call?

Participants are advised to join 15 minutes before the 8:00 a.m. ET start time, which means joining at 7:45 a.m. ET.